Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir
| Autor: | Guido Kruse, Dago Mazur, Heinz Richter, Michael Kurowski, Hartmut Stocker, Antje Breske, Norbert Banik, Ravi Walli |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Male
Immunology Organophosphonates Fosamprenavir Pharmacology Drug Administration Schedule Amprenavir Pharmacokinetics immune system diseases HIV Seronegativity medicine Immunology and Allergy Humans Protease inhibitor (pharmacology) Prospective Studies Furans Tenofovir Dose Modification Sulfonamides Cross-Over Studies Ritonavir Reverse-transcriptase inhibitor business.industry Adenine virus diseases HIV Protease Inhibitors Crossover study Organophosphates Infectious Diseases Anti-Retroviral Agents Area Under Curve Reverse Transcriptase Inhibitors Drug Therapy Combination Carbamates business medicine.drug |
| Zdroj: | AIDS (London, England). 21(10) |
| ISSN: | 0269-9370 |
| Popis: | The effect of tenofovir disoproxil fumarate (TDF) in combination with two boosted fosamprenavir regimens on amprenavir pharmacokinetic parameters was assessed in this prospective phase I crossover study with 30 healthy volunteers. The co-administration of TDF 300 mg once a day with fosamprenavir/ritonavir 1400/200 mg or 1400/100 mg once a day has no effect on the pharmacokinetics of amprenavir and results in non-significant increases of ritonavir pharmacokinetic parameters, suggesting that no dose modification is necessary when combining fosamprenavir/ritonavir with TDF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|